FSD Pharma Inc.
HUGE · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $120 | $126 | $145 |
| Gross Profit | $0 | -$120 | -$126 | -$145 |
| % Margin | – | – | – | – |
| R&D Expenses | $898 | $160 | -$31 | -$33 |
| G&A Expenses | $2,436 | $1,973 | $1,809 | $3,198 |
| SG&A Expenses | $2,436 | $1,973 | $1,970 | $3,198 |
| Sales & Mktg Exp. | $0 | $0 | $161 | $0 |
| Other Operating Expenses | $137 | $0 | $0 | $2,012 |
| Operating Expenses | $3,471 | $2,124 | $1,939 | $3,312 |
| Operating Income | -$3,457 | -$2,257 | -$2,065 | -$3,312 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $104 | $166 | $413 | $2,181 |
| Pre-Tax Income | -$3,352 | -$2,091 | -$1,697 | -$1,131 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,112 | -$1,903 | -$1,697 | -$1,131 |
| % Margin | – | – | – | – |
| EPS | -0.049 | -0.031 | -0.043 | -0.029 |
| % Growth | -55.4% | 27.6% | -49.1% | – |
| EPS Diluted | -0.079 | -0.048 | -0.043 | -0.029 |
| Weighted Avg Shares Out | 64,117 | 61,004 | 39,377 | 39,193 |
| Weighted Avg Shares Out Dil | 39,652 | 39,652 | 39,377 | 39,193 |
| Supplemental Information | – | – | – | – |
| Interest Income | $104 | $172 | $154 | $237 |
| Interest Expense | $8 | $12 | $0 | $0 |
| Depreciation & Amortization | $137 | $120 | $122 | $147 |
| EBITDA | -$3,207 | -$1,959 | -$1,529 | -$3,165 |
| % Margin | – | – | – | – |